



UNIVERSITY OF LEEDS

This is a repository copy of *Dry mouth diagnosis and saliva substitutes – A review from a textural perspective*.

White Rose Research Online URL for this paper:  
<https://eprints.whiterose.ac.uk/168643/>

Version: Accepted Version

---

**Article:**

Hu, J, Andablo-Reyes, E, Mighell, A [orcid.org/0000-0002-9624-6923](https://orcid.org/0000-0002-9624-6923) et al. (2 more authors) (2020) Dry mouth diagnosis and saliva substitutes – A review from a textural perspective. *Journal of Texture Studies*, 52 (2). pp. 141-156. ISSN 0022-4901

<https://doi.org/10.1111/jtxs.12575>

---

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

1           **Dry mouth diagnosis and saliva substitutes — A review**  
2                                   **from a textural perspective**

3  
4           Jing Hu<sup>a</sup>, Efren Andablo-Reyes<sup>a</sup>, Alan Mighell<sup>b</sup>, Sue Pavitt<sup>b</sup> and Anwesha Sarkar<sup>a\*</sup>

5  
6  
7  
8           <sup>a</sup>Food Colloids and Bioprocessing Group, School of Food Science and Nutrition, Faculty of  
9           Environment, University of Leeds, Leeds, LS2 9JT, UK

10          <sup>b</sup>School of Dentistry, Faculty of Medicine & Health, University of Leeds, Leeds, LS2 9LU,  
11          UK

12  
13  
14  
15  
16  
17  
18  
19          Corresponding author:

20          \*Prof. Anwesha Sarkar

21          Food Colloids and Bioprocessing Group,

22          School of Food Science and Nutrition, University of Leeds, Leeds LS2 9JT, UK.

23          E-mail address: [A.Sarkar@leeds.ac.uk](mailto:A.Sarkar@leeds.ac.uk) (A. Sarkar).

25 **Abstract**

26 The aim of this review is to assess the objective and subjective diagnosis, as well as  
27 symptomatic topical treatment of dry mouth conditions with a clear focus on textural  
28 perspective. We critically examine both the current practices as well as outline emerging  
29 possibilities in dry mouth diagnosis and treatment, including a patent scan for saliva  
30 substitutes. For diagnosis, salivary flow rates and patient-completed questionnaires have  
31 proven to be useful tools in clinical practice. To date, objective measurements of changes  
32 in mechanical properties of saliva *via* rheological, adsorption and tribological  
33 measurements and biochemical properties of saliva such as assessing protein, mucins  
34 (MUC5B) are seldom incorporated into clinical diagnostics; these robust diagnostic tools  
35 have been largely restricted to application in non-clinical settings. As for symptomatic  
36 treatments of dry mouth, four key agents including lubricating, thickening, adhesive and  
37 moisturizing agents have been identified covering the overall landscape of commercial  
38 saliva substitutes. Although thickening agents such as modified celluloses, polysaccharide  
39 gum, polyethylene glycol (PEG) *etc.* are most commonly employed saliva substitutes, they  
40 offer short-lived relief from dry mouth and generally do not provide boundary lubrication  
41 properties of real human saliva. Innovative technologies such as self-assembly, emulsion,  
42 liposomes, microgels are emerging as novel saliva substitutes that hold promise for  
43 alternative approaches for efficient moistening and lubrication of the oral mucosa. Their  
44 adoption into clinical practice will be dependent on their efficacies, duration of relief, ease  
45 of application by the practitioners and patient compliance.

46

47 **Keywords**

48 Dry mouth, xerostomia, diagnosis; symptomatic treatment; rheology; tribology; adsorption;  
49 thickening agents; mucoadhesives; lubricants

50 **1. Introduction**

51 Xerostomia, clinically defined as the subjective complaint of “dry mouth” has an estimated  
52 prevalence of approximately 20% in the general population. The prevalence increases to  
53 46% in older people aged >75 years, attributable in part to co-morbidity conditions and  
54 polymedication/ polypharmacy (Orellana *et al.*, 2006). Other causes, include, but not  
55 limited to, autoimmune exocrinopathy (*e.g.* primary Sjögren's syndrome (pSS), see Figure  
56 1), radiotherapy, sarcoidosis, HIV, hepatitis C and poorly-controlled diabetes mellitus  
57 (Mortazavi *et al.*, 2014). Xerostomia has a detrimental impact on quality of life affecting  
58 the most essential activities such as speaking and eating, with dysphagia inhibiting easy  
59 entrance of nutrients and increases the risks of malnutrition (Vainshtein *et al.*, 2016).  
60 Furthermore, it increases the risk of dental complications such as, caries, periodontal  
61 disease, candidiasis, and oral ulceration (Hopcraft and Tan, 2010). Xerostomia patients  
62 may have both hyposalivation and also alteration in salivary composition (Jellema *et al.*,  
63 2005; Mortazavi *et al.*, 2014; Villa and Avati, 2011). It is also worth noting that xerostomia  
64 patients may or may not have hyposalivation, which is a sign of abnormally lower salivary  
65 flow rate. For example, besides hyposalivation, dehydration (in elderly or dialysis patients)  
66 could also result in xerostomia (Mortazavi *et al.*, 2014). Xerostomia represents an  
67 enormous and growing health burden resulting from an increase in the global aging  
68 population and highlights the need for more effective topical dry mouth therapies (Ship *et*  
69 *al.*, 2002; Guggenheimer and Moore, 2003).

70

71

[Insert Figure 1 here]

72

73 Hyposalivation may lead to impairment in both the quantity and quality of saliva. Saliva,  
74 which is constituted mainly of water (99%), ions and proteinaceous compounds such as

75 mucins, amylases and others low molecular weight proteins (Sarkar *et al.*, 2019b), plays an  
76 important role in assuring the general and oral health as well as oral processing of food. It  
77 is generally the proteins that render saliva its rheological (viscosity, elasticity, stickiness),  
78 unique water-holding and lubrication properties (Alliende *et al.*, 2008; Tanasiewicz *et al.*,  
79 2016; Sarkar *et al.*, 2017). Various functions of saliva can be classified into two aspects: 1)  
80 *protection of the oral tissues* including lubrication, dilution, antimicrobial activity,  
81 cleansing activity, buffering action, remineralisation and tissue repair, and 2) *facilitating*  
82 *speech and oral processing* including food disintegration and digestion, bolus formation  
83 and swallowing, medium for flavour and aroma compounds diffusion (Carpenter, 2013;  
84 Dodds *et al.*, 2015).

85

86 To address dry mouth conditions, various topical therapies are employed. Typical therapies  
87 for dry mouth can be classified into three main groups: 1) salivary stimulants, 2)  
88 symptomatic treatments and 3) emerging regenerative and gene therapies (Salum *et al.*,  
89 2018).

90

91 **Salivary stimulants** are most commonly used but require some the salivary gland tissue to  
92 be functional. There are broadly three ways to stimulate the salivary secretion: acid,  
93 pharmaceutical and mechanical approaches. Citric and malic acids are the most commonly  
94 used as plant acids to stimulate the salivary secretion, the mechanism is that the topical  
95 acidification of the oral environment generates stimulation of salivary secretion to dilute  
96 the acid concentration (Han *et al.*, 2015; Salum *et al.*, 2018). Although improvement in dry  
97 mouth condition is shown by acid-based salivary stimulants, application of acid may  
98 increase the risk of dental erosion and hypersensitivity (da Mata *et al.*, 2009). Besides citric  
99 acid, umami taste substance like monosodium glutamate has been also found to stimulate

100 salivation (Sasano *et al.*, 2015).

101 Pilocarpine is the most commonly used pharmacological systemic medication given in a  
102 tablet form typically for relieving the symptoms of radiotherapy-induced xerostomia; it  
103 functions as muscarinic receptor agonists stimulating the secretion of saliva (Gil-Montoya  
104 *et al.*, 2016). However, based on a recent meta-analysis carried out using 39 studies that  
105 randomised 3520 participants (Riley *et al.*, 2017), it can be inferred that insufficient  
106 evidence exist to determine whether or not pilocarpine performed better or worse than a  
107 placebo in terms of treatment of xerostomia, salivary flow rate, survival, and quality of life.  
108 Thus, the pharmacological proposed benefits of pilocarpine can be questioned. In addition,  
109 pilocarpine, as a parasympathomimetic drug can lead to adverse pulmonary and  
110 cardiovascular side effects (Bernardi *et al.*, 2002) Mechanical salivary stimulation on the  
111 other hand includes use of chewing gums, acupuncture, and electrostimulation, among  
112 which sugar-free chewing gum is widely used because it is an easy way to mechanically  
113 stimulate salivary secretion without side effects (Davies, 2000; Han *et al.*, 2015; Łysik *et*  
114 *al.*, 2019).

115

116 **Symptomatic treatments** of dry mouth aim to moisten the oral mucosa (Narhi *et al.*, 1999).

117 The most frequently used symptomatic therapies include some form of water intake or  
118 hydrating materials and commercial saliva substitutes (Salum *et al.*, 2018). Although fluid  
119 intake can be useful for temporary relief of dry mouth symptoms (Łysik *et al.*, 2019), other  
120 functions of saliva such as coating and lubrication cannot be achieved by this approach.  
121 Existing commercial saliva substitutes in different forms like cleansers, sprays and gels are  
122 commonly based on thickening agent and moisturizing agent such as cellulose-based  
123 polymers (*e.g.* carboxymethyl cellulose (CMC)) and water-soluble polymers such as  
124 xanthan gum, glycerine and carbomer (Nieuw Amerongen and Veerman, 2003; Oh *et al.*,

125 2008; Han *et al.*, 2015). It is thus important to understand how far these polymers are  
126 successful in mimicking the techno-functionalities of real human saliva.

127

128 **Experimental regenerative and gene therapies** to ameliorate dry mouth conditions are  
129 currently under development. Regenerative therapies aim to attenuate salivary gland  
130 dysfunction, whereas stem cell and gene therapies aim to repair or prevent the salivary  
131 glands damage by gene transfer (Lombaert *et al.*, 2008; Samuni and Baum, 2011).

132

133 With this overview in mind, the aim of this review is to examine the measurable symptoms  
134 of dry mouth and saliva properties as well as critically examine the saliva substitutes  
135 focussing on textural aspects, such as lubrication and adsorption properties. In particular, a  
136 key objective is to provide a concise overview on several challenges associated with dry  
137 mouth diagnosis and therapy and discuss how the food textural research community might  
138 contribute to overcome them. Firstly, we discuss the various approaches for diagnosis of dry  
139 mouth to identify the objective versus subjective assessment of dry mouth conditions  
140 clearly highlighting the type of dry mouth therapies needed for most patients. We also  
141 highlight what kind of diagnostic tools can be used in the future to estimate the objective  
142 changes in biochemical, rheological, adsorption and tribological quality of saliva in dry  
143 mouth patients. Then, we critically analyse the common formulation agents of salivary  
144 substitutes highlighting the importance of tribological (*i.e.* friction, wear and lubrication)  
145 and adhesive properties. We also evaluate the patents over the last two decades to clearly  
146 pinpoint the latest advancements in development and highlight the development needed for  
147 salivary substitutes. Specifically, our focus is on salivary substitutes for symptomatic  
148 treatments. Formulations with active stimulants or medicines are beyond the scope of this  
149 review. Complementary reviews that focus on therapeutic trials of salivary substitutes are

150 available (Brennan *et al.*, 2002; Furness *et al.*, 2011; Salum *et al.*, 2018; Assery, 2019; See  
151 *et al.*, 2019). Abbreviations used throughout this review article are shown in Table 1.

152

153 [Insert Table 1 here]

154

155

## 156 **2. Diagnosis of dry mouth — objective and subjective assessment**

157 Generally, diagnosis of xerostomia starts with a thorough evaluation of medical history,  
158 focusing on the illness and past medical history of the patients in a clinical setting (Kho,  
159 2014). The key diagnosis method that have been used are generally subjective in nature  
160 such as questionnaires with rating scales for patients to fill and complementary objective  
161 assessment such as salivary secretion tests (Fox *et al.*, 1987). Although other tests  
162 deploying different imaging techniques (*e.g.* sialography and scintigraphy) were reported  
163 for dry mouth diagnosis, their usage is limited by the invasive character or high cost. In  
164 some medical settings, ultrasound is gaining interest as a useful diagnostic tool (Martire *et*  
165 *al.*, 2018). Other measurements that have been primarily used in research settings to assess  
166 salivary properties (*e.g.* salivary biochemical composition, adsorption, rheological and  
167 tribological tests) might also be utilized for aiding the diagnosis of dry mouth in the future  
168 and are discussed in the following sections.

169

### 170 *2.1 Questionnaires*

171 Questionnaires have played an important role in the evaluation of xerostomia. Since  
172 xerostomia is a subjective complaint, questionnaires on dry mouth do not always reflect the  
173 true hyposalivation. However, it is useful to identify certain questions that may predict true  
174 salivary dysfunction. For instance, evaluation of the relationship between subjective



175 symptoms and objective salivary flow often helps in more efficient diagnosis of  
176 hyposalivation than using questionnaires alone (van der Putten *et al.*, 2011). Table 2  
177 summaries the major xerostomia questionnaires developed from 1987 to 2007, where a  
178 relationship with objective salivary flow rates has been established, with three classical  
179 evaluation systems being included *i.e.* binary scale, categorical scoring scale and visual  
180 analogue scale (VAS).

181

182 [Insert Table 2 here]

183

184 Fox *et al.* (1987) employed useful questions in identifying salivary gland output  
185 dysfunction. They found that the responses to eating-dryness related questions (question 6-  
186 8) (Table 2) and saliva quantity question (question 9) were highly indicative of true salivary  
187 output deficiency reflected by stimulated and unstimulated flow, while questions  
188 concerning the presence or relief behaviour of mouth dryness (question 1-5) were not  
189 correlated significantly with the salivary hypofunction. The Xerostomia Inventory (XI)  
190 (Thomson *et al.*, 1999) was developed acting as a multi-item instrument estimating the  
191 severity of xerostomia symptoms with a continuous scale. Eleven items covering both  
192 experiential (experiences of awareness of dry mouth conditions *e.g.* “my mouth feels dry  
193 when eating a meal”) and behavioural (consequent behaviours *e.g.* “I sip liquids to aid in  
194 swallowing food”) aspects of patients’ experiences of dry mouth, and the responses to these  
195 items were summated to give a single XI scale score. Although the resulting score had a  
196 very low correlation with resting saliva flow rate, it had a positive and much stronger  
197 correlation than the standard single dry-mouth question responses, and the XI itself showed  
198 concurrent validity (Thomson and Williams, 2000).

199

200 Pai, Ghezzi, & Ship (2001) developed an eight-item VAS questionnaire for hyposalivation  
201 diagnosis. Seven items (Table 2) showed significant reliability, while only one question  
202 (“rate how much saliva is in your mouth”) regarding the quantity of saliva in mouth was  
203 not significantly correlated. Five items (1, 2, 3, 5 and 6) show significant validity with  
204 unstimulated submandibular saliva flow rates. Only item 1 and 6 were significantly  
205 correlated for stimulated submandibular flow rates, while only item 2 was significantly  
206 correlated for stimulated parotid flow rates.

207

208 Suh *et al.* (2007) developed a questionnaire with a combination of a binary scale,  
209 categorical scoring scale and VAS to evaluate the relationship between subjective dry  
210 mouth symptoms and salivary flow rate. They reported that the duration and frequency of  
211 oral dryness or usage of chewing gum are not significantly associated with salivary flow  
212 rate, while dry mouth-related symptoms and behaviours like awakening from sleep at night  
213 because of oral dryness were significantly associated with whole salivary flow rate.  
214 Comparing all these four questionnaires (Table 2) and their relationship with salivary flow  
215 rate indicates that the questions regarding the behaviour to relieve dry mouth like chewing  
216 gum and candy intake are less related to salivary flow rate, while dry mouth symptoms and  
217 eating behaviour related questions are more predictive for diagnosis of salivary dysfunction.

218

## 219 2.2 Salivary secretion test

220 Salivary secretion test is the most advocated clinical method for diagnosis of salivary  
221 dysfunction, which is typically defined by an unstimulated whole saliva flow rate *i.e.* less  
222 than 0.1 mL/min or a stimulated whole saliva flow rate *i.e.* less than 0.5-0.7 mL/min  
223 (Löfgren *et al.*, 2012). Accurate and standardized method for measurement of salivary  
224 secretion is essential since the quality and quantity of saliva are significantly affected by

225 the sources and methods used for saliva collection (Navazesh and Kumar, 2008). Different  
226 sources for saliva collection are from mixed or individual glands corresponding to whole  
227 saliva and individual gland saliva, respectively. While the unstimulated saliva is mainly  
228 secreted by submandibular glands, the stimulated saliva is mainly contributed by parotid  
229 glands (Navazesh and Kumar, 2008). Methods of whole saliva collection include draining  
230 method, spitting method, suction method and swab method (Navazesh, 1993). Among them,  
231 draining and spitting methods by dripping saliva off the lower lip or spitting the saliva from  
232 the floor of the mouth are reproducible and reliable for unstimulated whole saliva collection  
233 (Navazesh and Christensen, 1982). While the suction method and swab method by saliva  
234 ejector or pre-weighed saliva adsorption swab were found to be less reliable with some  
235 degree of variability, and thus were not recommended.

236

237 To stimulate whole saliva secretion, standard-sized gum base, paraffin wax, rubber bands  
238 and citric acid are commonly used, and spitting method is suitable for stimulated whole  
239 saliva collection (Navazesh and Kumar, 2008). As for individual gland saliva collection,  
240 custom-made collection devices are commonly required. For example, the parotid gland  
241 saliva is typically collected by the Lashley cup or Carlson–Crittenden collector, the  
242 submandibular and sublingual glands saliva is commonly collected through Wharton duct,  
243 and the minor salivary gland secretions can be collected by filter paper (Lashley, 1916;  
244 Eliasson and Carlén, 2010). By using the afore-mentioned collection methods, the salivary  
245 flow rate can be calculated as weight or volume of collected saliva divided by collection  
246 period time (Navazesh and Kumar, 2008). Saliva collection from individual gland is more  
247 reliable compared with whole saliva collection which, is a mixture of saliva, fluids, debris  
248 and oral mucosal cells. The flow rate of unstimulated parotid saliva was reported as 0.04  
249 and 0.00 mL/min/gland for healthy controls and pSS patients, respectively (Pedersen *et al.*,

250 2005). Therefore, the techniques for individual glands are tedious and impractical with  
251 extremely limited salivary flow rate (Navazesh and Kumar, 2008)

252

### 253 *2.3 Potential diagnostic tests for use in future*

254 Salivary quantity and flow rate vary dramatically within and between individuals. In  
255 addition, accurate assessment of dry mouth according to the quantity of saliva is difficult.  
256 Therefore, biochemical and mechanical measurements offer promise to support diagnostic  
257 tests for dry mouth. Saliva quality in terms of its compositional feature and mechanical  
258 properties such as adsorption, rheological and tribological properties have been studied in  
259 research setting over the last decade. These tests can be employed to understand the changes  
260 in salivary quality in mechanical terms in dry mouth patients, which is discussed in the  
261 following subsections.

262

#### 263 *2.3.1 Biochemical composition measurements*

264 One obvious change in the saliva of dry mouth patients is the alteration in biochemical  
265 composition, while detailed changes in saliva depends on the particular cause of  
266 hyposalivation. For example, increased  $\text{Na}^+$ ,  $\text{K}^+$ ,  $\text{Cl}^-$ ,  $\text{Ca}^{2+}$ , immunoglobulin A (IgA) and  
267 amylase were found in patients with oral sensorial complaints who were not having any  
268 psychiatric disorders or any major diseases such as cancer or sepsis (Granot and Nagler,  
269 2005). Increased calcium, parathyroid hormone (PTH) and cortisol concentrations, in  
270 contrast to decreased oestrogen and progesterone concentrations were found in menopausal  
271 women with xerostomia (Agha-Hosseini and Moosavi, 2013). Reduced sulfation of mucin  
272 was found in pSS patients with xerostomia (Alliende *et al.*, 2008).

273 Mucin plays an important role in the rheological, tribological and surface adsorption  
274 properties of saliva, mainly because of their highly hydrated oligosaccharide side-chains,

275 “bottlebrush” configuration *i.e.* oligosaccharide chains like “brushes” are attached to  
276 protein backbone of mucin and negatively charged sialic acid residues (Coles *et al.*, 2010;  
277 Xu *et al.*, 2019). MUC5B (~1 to 20 MDa) and MUC7 (~150 kDa) are two major physically  
278 distinct salivary mucins that are rich in *O*-glycosylation with an extended linear structure  
279 and a high degree of sialylation (Thomsson *et al.*, 2002; Morzel *et al.*, 2014). Structural  
280 changes of these two mucins have been found in dry mouth patients (Alliende *et al.*, 2008;  
281 Dijkema *et al.*, 2012; Chaudhury *et al.*, 2015; Chaudhury *et al.*, 2016). For example, relative  
282 levels of sulfo-MUC5B were found to be substantially decreased in gland extracts from  
283 patients with Sjögren syndrome and dry mouth (n=10) as compared with the healthy control  
284 group (n=9), indicating a notable reduction of MUC5B sulfation level in the former group  
285 (Figure 2a) (Alliende *et al.*, 2008). Reduced MUC5B and MUC7 glycosylation were also  
286 found in patients with Sjögren syndrome associated oral dryness, although the mucin  
287 concentrations were found to be similar between the patients and the control group  
288 (Chaudhury *et al.*, 2016). These findings indicate that changes in mucin quality are  
289 indicative of dry mouth symptoms and could be a potential objective diagnostic tool for  
290 xerostomia patients with pSS.

291

### 292 2.3.2 Rheological measurements

293 Researchers have demonstrated that rheological properties of saliva alter in dry mouth  
294 patients (Chaudhury *et al.*, 2015) or with growing age (Pushpass *et al.*, 2019a). Figure 2b  
295 shows that patients complaining of xerostomia (n=34) exhibited significantly lower saliva  
296 spinnbarkeit (*i.e.* extensional viscosity) in comparison to healthy control subjects (n=30)  
297 (Chaudhury *et al.*, 2015). Such statistically significant reduction ( $p < 0.05$ ) in saliva  
298 spinnbarkeit is also shown in another study with Sjögren’s patients (n=21) as compared to  
299 healthy controls (n=30) (Chaudhury *et al.*, 2016).

300

301

[Insert Figure 2 here]

302

303 Viscosity is another important rheological property which is usually used as an essential  
304 objective assessment of mechanical properties of both saliva and salivary substitutes.

305 Viscosity changes of unstimulated human saliva in different age and gender groups have  
306 been reported (Gittings *et al.*, 2015). As shown in Figure 2c, the viscosity of unstimulated  
307 saliva for the age group 28-35 (n=8) was significantly higher than that of 20-27 (n=22) at  
308 low shear rate region. The viscosities of unstimulated saliva in males (n=13) were reported  
309 to be higher than those in females (n=17). In another study, a slightly higher viscosity was  
310 found for unstimulated whole saliva of younger groups ( $1.73 \pm 0.2$  mPa·s, 18-30 years old,  
311 n=30) compared with older groups ( $1.55 \pm 0.2$  mPa·s, 60+ years old, n=24) (Pushpass *et*  
312 *al.*, 2019b). To the best of authors' knowledge, no study exist comparing the salivary shear  
313 viscosity of dry mouth patients versus healthy controls. Nevertheless, these aforementioned  
314 salivary viscosity measurements suggest potential use of flow curve as a reproducible tool  
315 to indicate age-dependent alteration of salivary viscosity in dry mouth patients in the future  
316 (Schein *et al.*, 1999).

317

### 318 2.3.3 Adsorption measurements.

319 Both MUC5B and MUC7 are major constituents of the mucosal pellicle which coats and  
320 protects the oral surface (Thomsson *et al.*, 2002; Morzel *et al.*, 2014). Therefore, changes  
321 of these two mucins can lead to an alteration of pellicle properties. One quantitative  
322 approach to measure the adsorption properties of salivary pellicles is quartz crystal  
323 microbalance with dissipation monitoring (QCM-D), which is a real-time, surface sensitive  
324 technique for analysis of layer properties, surface phenomena, and to derive quantitative

325 information on thin film formation on a substrate (Veeregowda *et al.*, 2012; Ash *et al.*,  
326 2014). For example, the real-time dissipation and frequency profiles of whole mouth saliva  
327 (n=10) pellicle and parotid saliva (n=10) pellicle adsorbed onto hydroxyapatite (main  
328 component of enamel) surfaces are shown in Figure 2d (Ash *et al.*, 2014). A rapid decrease  
329 in frequency of both whole mouth saliva and parotid saliva pellicle is observed. In  
330 comparison to a plateau reached after 20 minutes of whole mouth saliva addition, the  
331 frequency of parotid saliva keeps a decreasing trend in the overall 120 minutes time period,  
332 indicating a continuous saliva pellicle adsorption. A slower increase in dissipation of  
333 parotid saliva pellicle compared to whole saliva was observed, indicating a more rigid layer  
334 being formed by parotid saliva. Flow rate changes of whole saliva and parotid saliva with  
335 age were also found to be different, with a significant lower whole salivary flow in 80+  
336 individuals in compared with no age-related decline for parotid saliva (Percival *et al.*, 1994).  
337 In this way, differences in rate and degree of adsorption between whole and parotid saliva  
338 can be used as a suitable analytical tool to evaluate the changes in the saliva pellicle  
339 properties of dry mouth patients, which has received limited attention so far in dry mouth  
340 diagnosis.

341

342

#### 343 2.3.4 Tribological measurements

344 Poor lubrication performance is a key complaint in dry mouth conditions and therefore  
345 tribological analysis *i.e.* measuring the frictional properties could be an important  
346 diagnostic tool. The comparison of dry mouth patient (n=4) and healthy individuals (n=4)  
347 salivary lubrication has been once implemented in a tongue-enamel friction system (an *ex*  
348 *vivo* laboratory-based friction tester) with the tooth enamel sliding against the porcine  
349 tongue for 10 cycles mimicking dry mouth (Figure 2e) (Wan *et al.*, 2020). Then, a drop of

350 stimulated whole saliva from healthy controls or Sjögren syndrome patients was placed and  
351 spread for 4 cycles, followed by another drop of buffer for 4 cycles and finally another drop  
352 of healthy or patient saliva. A sharp decrease in friction coefficient from around 2.5 in dry  
353 mouth condition to 0.5 was observed after the addition of healthy or patient saliva,  
354 representing the relief feeling after rinsing the mouth with a particular lubricant in dry  
355 mouth patients. The upcoming duration period with remaining low friction coefficient  
356 under continuous sliding was called 'relief period'. As shown in Figure 2e, healthy saliva  
357 resulted in a longer 'relief period' compared to that of patient saliva, indicating the  
358 relatively weak lubrication performance of dry mouth patients' saliva.

359

360 To further promote the usage of these emerging mechanical, chemical and adsorption tests,  
361 there are still some aspects that need improved. For instance, reduction in the volume of  
362 saliva samples needed for measurements, decreasing the time of testing and the cost of  
363 measurements will be the obvious way forward to make these tests suitable in a clinical  
364 setting.

365

### 366 **3. Salivary substitutes**

367 Salivary substitutes are frequently used as symptomatic treatments for patients with  
368 decreased salivary flow rate or poor salivary quality. Commercial salivary substitutes can  
369 be categorized into eight platform technologies according to their functions (Figure 3). Four  
370 key functions of saliva substitutes *i.e.* lubricating, thickening, adhesive and moisturizing  
371 are discussed in this review. These functions are related directly to the wear and dryness of  
372 oral surfaces. Buffering functions are needed to neutralize product pH and protect dental  
373 health, while optional agent such as sweetener, surfactant, colorant and preservative are  
374 usually added to further improve patient's acceptance and adherence (Scott *et al.*, 2010).



375 Although saliva stimulant agent is also included in some artificial saliva to stimulate the  
376 salivary flow (Furness *et al.*, 2011), such stimulants do not mimic any salivary functions  
377 and thus not discussed in this review.

378

379 [Insert Figure 3 here]

380

### 381 *3.1 Thickening and lubricating agents*

382 Hydrocolloids with a large number of hydroxyl (-OH) groups such as xanthan, guar gum,  
383 starch, alginate, pectin, gellan, agar, carrageenan and cellulose derivatives are commonly  
384 used as thickening agents not only in food but also in saliva substitutes (Van der Reijden  
385 *et al.*, 1994; Saha and Bhattacharya, 2010). Thickening agent is usually added to increase  
386 the viscosity of commercial salivary substitute products, such as high-viscosity saliva  
387 substitutes or gels with an objective to extend the duration of dry mouth relief (Partenhauser  
388 and Bernkop-Schnürch, 2016). For instance, hydroxyethyl cellulose- (HEC) based Biotène  
389 Oral balance dry mouth system (OB) and BioXtra (BX) gel have similar composition, while  
390 BX is more viscous than OB (23.0 vs 16.8 Pa s) (Shahdad *et al.*, 2005). A small double-  
391 blind, crossover study (n=20 xerostomia patients) found that the moisturizing effect of OB  
392 gel lasted no more than 2 hours. However, nine patients reported the effect of BX gel lasting  
393 for more than 2 hours. This supports the beneficial effects of thickening agents in enhancing  
394 the relief period.

395

396 One of the most important function of saliva is lubrication, which minimize the wear of  
397 mucosal surfaces and therefore supports food oral processing (Carpenter, 2013). Therefore,  
398 it is crucial for salivary substitutes to exhibit similar or even better lubrication properties  
399 as compared to healthy human saliva. Typical manifestation of lubrication properties is  
400 Stribeck curve with friction coefficient plotted as a function of film thickness *i.e.*

401 entrainment speed (speed at which the lubricant is entrained into the contact) multiplied by  
402 the lubricant viscosity and divided by the normal force (Sarkar *et al.*, 2019a). According to  
403 the adsorbed film thickness between two moving surfaces, the Stribeck curve can be  
404 divided into three regimes: boundary, mixed and hydrodynamic lubrication regime.  
405 Boundary lubrication regime occurs at low entrainment speeds where the moving surfaces  
406 are almost in full contact. In this regime, the surface characteristics account for the friction  
407 coefficient. So, a tightly adhered lubricant of thickness of few molecules to the moving  
408 surfaces can facilitate boundary lubrication (Coles *et al.*, 2010). As the entrainment speed  
409 increases, the hydrodynamic forces of fluid rise causing a reduction in friction coefficient.  
410 Then, in hydrodynamic lubrication regime, the surfaces are fully separated by fluid where  
411 viscosity plays an important role (Sarkar *et al.*, 2019a). Whole unstimulated saliva shows  
412 excellent lubricating behaviour in all the three regimes, which is probably due to the  
413 presence of salivary proteins that contribute to hydration lubrication (Xu *et al.*, 2020).  
414 Highly glycosylated mucins (MUC5B) and other low molecular weight proteins such as  
415 lactoferrin in synergy contributes to both boundary and fluid film lubrication of salivary  
416 pellicle (Xu *et al.*, 2020). Especially the aforementioned MUC5B, which is dysregulated in  
417 dry mouth patients, is a major gel-forming mucin in human saliva (Wickström *et al.*, 1998).  
418 Therefore, mucin-based salivary substitutes have been also developed. Saliva Orthana<sup>®</sup> is  
419 the only saliva substitute containing an animal-derived mucin currently on the market,  
420 probably due to the risk of transmissible spongiform encephalopathy (Kelly *et al.*, 2004;  
421 Partenhauser and Bernkop-Schnürch, 2016).

422

423 In addition to mucin, other commonly used lubricating agents that act in the hydrodynamic  
424 regime include glycerine, polyethylene glycol (PEG), cellulose-based polymer such as  
425 HEC and carboxymethyl cellulose (CMC), and water-soluble polymers such as carrageenan

426 and xanthan gum (van der Reijden *et al.*, 1996; Vinke *et al.*, 2020). However, unlike saliva,  
427 the afore-mentioned substitutes do not offer any boundary lubrication *i.e.* lubrication in the  
428 low speeds, which is more relevant in oral conditions. Glycerine and water-soluble  
429 polymers also work as thickening agents with high shear viscosity at low concentrations  
430 (de Vicente *et al.*, 2005). Glycerine-based salivary substitutes were found to be less  
431 effective in boundary lubrication in comparison to mucin-based ones, despite an  
432 approximately 300 times greater viscosity than other fluid samples (Aguirre *et al.*, 1989).  
433  
434 Hydrodynamic lubrication behaviour of mucin and CMC-based salivary substitutes have  
435 been widely studied (Vissink *et al.*, 1983; Hatton *et al.*, 1987; Christersson *et al.*, 2000),  
436 saliva substitutes based on mucin has been proven to provide better lubrication than CMC  
437 in biocompatible hard interface (tooth-glass interface) with relative lubrication values ( $77$   
438  $\pm 6\%$  of the positive control) comparable to those of whole human saliva ( $63 \pm 7\%$  of the  
439 positive control) (Hatton *et al.*, 1987). Clinical studies (n=137 dry mouth patients) (Vissink  
440 *et al.*, 1983) have also found higher patient preference for mucin-containing saliva  
441 substitute over the CMC ones. Such performance may result from more similarity of mucin-  
442 containing artificial saliva and real human saliva as compared to CMC counterparts. On the  
443 other hand, a recent oral lubrication study of various commercially available saliva  
444 substitutes containing active ingredients such as mucin, HEC, PEG-hydrogenated castor oil,  
445 xanthan gum, CMC, plant polysaccharide and oxidized glycerol triesters found that all  
446 those saliva substitutes lack optimum lubricating properties (Vinke *et al.*, 2020). Therefore,  
447 more effective combination of thickening and lubricating agents and standardised  
448 subjective and objective clinical test to understand the effect of the salivary substitutes are  
449 needed for development of effective saliva substitutes that mimic real salivary lubrication.  
450

### 451 3.2 Adhesive and moisturizing agent

452 Adhesive agent is often added to saliva substitutes facilitating the formation of a coating,  
453 which provides sufficient barrier for oral tissues from external irritation. Mucoadhesive  
454 materials are ideal adhesive agents, which demonstrate attractive interactions with mucosal  
455 surface (Partenhauser and Bernkop-Schnürch, 2016). Such mucoadhesive materials usually  
456 possess good wettability properties with numerous hydrogen bond forming groups (Ben-  
457 Zion and Nussinovitch, 1997), therefore can also act as moisturizing agent in saliva  
458 substitutes. Effective mucoadhesive materials can spread over and diffuse into substrate  
459 increasing the surface area of contact, through dominant attractive forces such as covalent  
460 force, hydrogen bond or electrostatic interaction (Lee *et al.*, 2000). According to the origin,  
461 mucoadhesive materials can be classified into four types (Partenhauser and Bernkop-  
462 Schnürch, 2016): 1) natural mucoadhesive materials, such as guar gum, xanthan gum,  
463 starch, pectin and gellan gum, chitosan, natural glycosaminoglycans such as hyaluronic  
464 acid (HA), and natural polypeptides such as gelatine; 2) semi-synthetic mucoadhesive  
465 materials, such as cellulose ethers *e.g.* hydroxypropyl cellulose (HPC) and methyl cellulose  
466 (MC), HEC and CMC; 3) synthetic mucoadhesive materials, such as PEG and polyacrylic  
467 acid (PAA, also known as carbomer) and 4) innovative mucoadhesive materials, such as  
468 thiolated polymers *e.g.* thiolated chitosan, thiolated PAA and thiolated xanthan gum.  
469 Among these materials, some are anionic polymers such as CMC, HA, PAA, pectin and  
470 gellan gum are rich in carboxylic moiety (-COOH) and function by virtue of hydrogen  
471 bonding with mucosal surfaces (Park and Robinson, 1987). Some materials are cationic  
472 polymers such as chitosan and cationic HEC which are hypothesized to undergo  
473 electrostatic interactions with residual anionic mucin in the mucus layer of the dry mouth  
474 patients, where hydrogen bonding and hydrophobic effects also happen, resulting in the  
475 enhanced mucoadhesive property (He *et al.*, 1998; Sogias *et al.*, 2008). Non-ionic polymers

476 such as PEG and MC can also be used as adhesive agents. Although PEG lacks the  
477 functional groups *e.g.* carboxylic, hydroxyl or amine groups (Smart, 2005), it can  
478 interpenetrate into the mucus layer by diffusion and facilitate mucoadhesion (Serra *et al.*,  
479 2006). As for thiolated polymers, they can form covalent disulfide bridges with the mucus  
480 layer *via* thiol–disulfide exchange reactions with mucus, thereby achieving strong  
481 mucoadhesion.

482

483 The bio-adhesion effectiveness of salivary substitutes containing proper adhesive and  
484 moisturizing agent has been proven. For example, bio-adhesive properties of three saliva  
485 substitutes including Biotène® (HEC based), Oasis® (PEG and xanthan gum based) and  
486 Saliva Orthana® (mucin based) have been proven to be close to those of real human saliva  
487 tested by *ex vivo* indentation tests with pig tongues indicating adhesion force (Pailler-Mattei  
488 *et al.*, 2015). In the meantime, CMC, HEC or PEG-hydrogenated castor-based saliva  
489 substitutes are widely investigated. For example, in a study with 17 commonly applied  
490 saliva substitutes, only 3 items did not contain the aforementioned three mucoadhesive  
491 materials (Vinke *et al.*, 2020). Four of these tested 17 saliva substitutes including BioXtra  
492 gel (HEC based), Biotène gel (HEC based), Gum Hydral gel (xanthan gum, carrageenan  
493 and PEG-hydrogenated castor oil based) and Glandosane spray (CMC based) showed  
494 capability to increase the adsorption of saliva to these substitutes-coated surface of quartz  
495 crystals in QCM-D. The bio-adhesive properties of three saliva substitutes including  
496 Biotène® (HEC based), Oasis (PEG 60 hydrogenated based) and Saliva Orthana® (mucin  
497 based) were also reported to be similar to those of human saliva on pig tongues *ex-vivo*,  
498 except for the Aequasyl® (oxidised glycerol triesters based) (Pailler-Mattei *et al.*, 2015).  
499 However, in another study comparing the film-forming properties of CMC-based MAS 84  
500 or porcine mucin-based Saliva Orthana®, CMC-based saliva substitute showed negligible

501 adsorption on hydrophilic or hydrophobic silica surfaces tested by ellipsometry, while  
502 mucin-based Saliva Orthana<sup>®</sup> was adsorbed onto hydrophobic surfaces ( $1.4 \text{ mg m}^{-2}$ )  
503 although not as effective as whole saliva ( $2.8 \text{ mg m}^{-2}$ ) (Christersson *et al.*, 2000).

504

505 As for moisturizing properties, contact angle measurements have been frequently used. For  
506 example, the contact angle of CMC-based and mucin-based saliva substitutes on human  
507 mucosa were comparable or even lower than that of human whole saliva on human mucosa  
508 layer, indicating good wetting properties of these saliva substitutes (Vissink *et al.*, 1986).  
509 Contact angle of saliva substitutes on buccal epithelial cell surface was also studied,  
510 proving a very high wettability of xylitol based mouth spray ( $38.78 \pm 1.78^\circ$ ) compared with  
511  $71.64 \pm 2.20^\circ$  of unstimulated whole saliva (Spirk *et al.*, 2019). While contact angle of  
512 CMC based (Sialin-Sigma<sup>®</sup>) and macrogol based (Glandomed<sup>®</sup>) were  $86.97 \pm 5.91^\circ$  and  
513  $89.83 \pm 1.49^\circ$  respectively, indicating poor wettability. These studies indicate the  
514 importance of standardised evaluation method for adsorption properties of saliva  
515 substitutes, such as standard surface, equipment and adsorption protocol.

516

517 Many clinical tests have also evaluated the effectiveness of aforementioned salivary  
518 substitutes. Furness *et al.* (2011) assessed the risk of bias of 36 randomised controlled  
519 trials on topical interventions such as CMC, mucin, glycerol, xanthum gum, HEC citric  
520 acid and carbopol based salivary substitute gel or spray, in terms of random sequence  
521 generation, allocation concealment, blinding, incomplete outcome data, selective reporting  
522 and other potential sources of bias. However, no strong evidence was found for the  
523 effectiveness of any salivary substitutes due to the high risk of bias in most of the clinical  
524 trials. Therefore, further studies are needed for the design of promising salivary substitutes  
525 and controlled trials to guide clinical care.

526

527 *3.3 Innovative technologies for salivary substitutes*

528 In addition to these active agents added for different aspects of properties, some innovative  
529 technologies were also investigated for potential usage in salivary substitutes. For example,  
530 a self-assembly of mucin and lactoferrin has been shown by Xu *et al.* (2020), demonstrating  
531 promising wettability of hydrophobic surfaces, which was restored over 72 hours with  
532 similar adsorption compared to that of real human saliva. The study demonstrated that a  
533 synergistic lubrication by salivary components *i.e.* mucin and low molecular weight protein  
534 such as lactoferrin was key to mimic the lubricity (*i.e.* similar friction coefficients) of real  
535 human saliva (Xu *et al.*, 2020). The important role of low molecular weight proteins in  
536 saliva lubrication were also mentioned in other papers (Singh *et al.*, 2014; Yakubov *et al.*,  
537 2015). This indicates future potential of such proteinaceous self-assembly as a novel  
538 technique to create salivary substitutes with better adsorption, lubrication and wettability  
539 properties. For instance, recently, in our laboratory, we fabricated microgel-reinforced  
540 hydrogel as a new, patented aqueous lubricant formulation (Hu *et al.*, 2020) that performs  
541 better than saliva in terms of lubrication performance. The synergistic effect between the  
542 components *i.e.* lactoferrin microgel and  $\kappa$ -carrageenan hydrogel was demonstrated to offer  
543 both boundary and viscous lubrication, respectively, resulting in significantly lower friction  
544 coefficient values in comparison to the sole components as well as real human saliva. The  
545 lubricant offers prospects in terms of acting as a salivary substitute in the future.

546

547 Table 3 summarises patents on salivary substitutes that have surfaced in the last 20 years  
548 focusing on textural property improvements.

549

550

[Insert Table 3 here]

551

552 For instance, polymers with gelling abilities might be converted into microgels thereby  
553 potentially improving the hydration properties. Gellan gum-based microgel spray has been  
554 evaluated for prevention of oral dryness by *in vitro* study and clinical test (Table 3). Results  
555 showed that microgels were particularly effective for relieving dry mouth symptoms for  
556 patients with cancer (Ota *et al.*, 2012). In another instance, liposomes prepared by  
557 surrounding water with lipid bilayers have also demonstrated promise to act as effective  
558 salivary substitutes due to slower water release and prolonged moisture protection. For  
559 example, phosphatidylcholine-based (soya-PC) liposomes have shown to obtain higher  
560 water binding capacity than pectin (Adamczak *et al.*, 2016). Polymer-coated liposomes  
561 showed even better properties with improved water binding capacity as compared to non-  
562 coated ones. High mucoadhesion and mucosal biocompatibility of polymer-coated  
563 liposomes were also demonstrated (Table 3). These findings indicate the great potential of  
564 liposomes and its derivatives in hydrating oral mucosa and relieving dry mouth symptoms.

565

566 Oil-based emulsions have also been investigated as potential saliva substitutes. The  
567 viscoelastic properties of lecithin-based emulsions were observed, with viscous behaviour  
568 at low frequency and increased elasticity at higher frequencies (Table 3). Clinical tests of  
569 lecithin-based emulsion showed superior retention compared with water and similar  
570 retention to that of methylcellulose solution. However, another clinical study of lecithin-  
571 based emulsion showed that no significant benefit of oily emulsion for relief of xerostomia  
572 (Table 3). These studies indicate larger well-designed clinical studies for product property  
573 assessment are needed to understand the future applications of these innovative  
574 technologies.

575



576 A variety of measurements were used to evaluate the properties of these patented  
577 formulations such as clinical trials, rheological tests, adsorption tests, wettability tests and  
578 tribological tests (Table 3). Among them, the most widely used evaluation is rheological  
579 tests. One major trend in these patents is the use of food-sourced components such as yam,  
580 okra and plant oil, since they are natural material easily accepted by human (Table 3). For  
581 example, similar viscoelastic properties were found between yam solutions and human  
582 saliva (Kho and Park 2011). In summary, the saliva substitute development is a highly  
583 topical area of research and more efficient substitutes emulating the boundary lubrication  
584 properties of saliva appear to be a gap in the literature.

585

586

587

#### 588 **4. Conclusions**

589 This review provides a comprehensive summary of various diagnostic tools for assessment  
590 of dry mouth conditions and examined the salivary substitutes providing textural properties  
591 emulating those of real human saliva for treatment of dry mouth condition. In terms of  
592 diagnosis, salivary flow rate test and questionnaire are commonly used in clinical setting  
593 with subjective questionnaires being the most common approach. However, to date, there  
594 has been little attention on assessing the alternation in biochemical composition and  
595 mechanical properties of saliva in dry mouth patients. Biochemical composition,  
596 rheological, adsorption and tribological properties are important feature of saliva  
597 contributing to its unique functions, which are widely studied by researchers. It is thus  
598 crucial to employ these mechanical measurements on saliva from dry mouth patients in  
599 order to rationally tailor the kind of saliva substitute needed for their relief. For instance,  
600 if the dry mouth patient has residual saliva which contains high levels of lubricating

601 salivary proteins but lacking in the hydrodynamic properties, then a thickening agent might  
602 be an ideal solution. However, if the salivary quality of the dry mouth patient suffers from  
603 lack of adsorption and boundary lubrication properties that are measured using QCM-D  
604 and tribological analyses, respectively, more effective saliva substitute that can act as  
605 boundary lubricants should be approached. Such group-personalized design of saliva  
606 substitutes would likely provide optimum treatment outcome of xerostomia. Another  
607 important challenge is to find a correlation between objectively measured salivary  
608 properties (*e.g.* lubrication, adsorption, mucin content) and subjective assessment of dry  
609 mouth. The lack of correlations hinder clinical adoption of these techniques for routine  
610 evaluation of dry mouth conditions by dental practitioners.

611

612 For treatment, eight composition agents have been identified within the commercial saliva  
613 substitute products, while four of them were directly related to relief of oral dryness  
614 including lubricating, thickening, adhesive and moisturizing agents. Materials such as  
615 polysaccharides, mucin and cellulose-based derivatives were commonly discussed  
616 materials in literature. In addition to these commonly used component agents, innovative  
617 development of saliva substitutes were summarised at the end of this review, indicating a  
618 trend of employing food-related materials such as yam, okra and colloidal technologies,  
619 such as self-assembly, emulsion, liposomes and microgels. In summary, further pre-clinical  
620 characterization of innovative technologies are needed and clear benefits of these  
621 technologies in terms of mucoadhesion, lubrication ad relief period over existing saliva  
622 substitutes need to be established before such materials can be used for clinical trials.

623

624 **Acknowledgements**

625 Funding from the European Research Council (ERC) under the European Union's Horizon  
626 2020 research and innovation programme (grant agreement n° 757993 and 89044) is  
627 acknowledged.

628

629 **Ethical Statements**

630 **Conflict of Interest:** The authors declare that they do not have any conflict of interest.

631 **Ethical Review:** This study does not involve any human or animal testing.

632 **Informed Consent:** Not applicable.

633 **References**

- 634 ADAMCZAK, MI., MARTINSEN, ØG., SMISTAD, G., and HIORTH, M. 2016. Water  
635 sorption properties of HM-pectin and liposomes intended to alleviate dry mouth.  
636 *International Journal of Pharmaceutics* 15, 201-6.
- 637 AGHA-HOSSEINI, F., and MOOSAVI, M.-S. 2013. An evidence-based review literature  
638 about risk indicators and management of unknown-origin xerostomia. *Journal of*  
639 *Dentistry (Tehran, Iran)* 10, 273-282.
- 640 AGUIRRE, A., MENDOZA, B., REDDY, M.S., SCANNAPIECO, F.A., LEVINE, M.J., and  
641 HATTON, M.N. 1989. Lubrication of selected salivary molecules and artificial salivas.  
642 *Dysphagia* 4, 95-100.
- 643 ALLIENDE, C., KWON, Y.J., BRITO, M., MOLINA, C., AGUILERA, S., PÉREZ, P.,  
644 LEYTON, L., QUEST, A.F., MANDEL, U., VEERMAN, E., ESPINOSA, M.,  
645 CLAUSEN, H., LEYTON, C., ROMO, R., and GONZÁLEZ, M.J. 2008. Reduced  
646 sulfation of MUC5B is linked to xerostomia in patients with Sjögren syndrome. *Annals*  
647 *of the Rheumatic Diseases* 67, 1480-1487.
- 648 ASH, A., BURNETT, G.R., PARKER, R., RIDOUT, M.J., RIGBY, N.M., and WILDE, P.J.  
649 2014. Structural characterisation of parotid and whole mouth salivary pellicles  
650 adsorbed onto DPI and QCMD hydroxyapatite sensors. *Colloids and Surfaces B:*  
651 *Biointerfaces* 116, 603-611.
- 652 ASSERY, M.K.A. 2019. Efficacy of artificial salivary substitutes in treatment of xerostomia:  
653 A systematic review. *Journal of Pharmacy & Bioallied Sciences* 11, S1-s12.
- 654 BANERJEE, R., and GUHASARKAR, S. 2012. Self assembled nanostructured saliva  
655 substitutes. Patent number WO2012095774A1.
- 656 BEN-ZION, O., and NUSSINOVITCH, A. 1997. Physical properties of hydrocolloid wet glues.  
657 *Food Hydrocolloids* 11, 429-442.
- 658 BERNARDI, R., PERIN, C., BECKER, F.L., RAMOS, G.Z., GHENO, G.Z., LOPES, L.R.,  
659 PIRES, M., and BARROS, H.M.T. 2002. Effect of pilocarpine mouthwash on salivary  
660 flow. *Brazilian Journal of Medical and Biological Research.* 35, 105-110.

- 661 BRENNAN, M.T., SHARIFF, G., LOCKHART, P.B., and FOX, P.C. 2002. Treatment of  
662 xerostomia: a systematic review of therapeutic trials. *Dental Clinics of North America*  
663 46, 847-856.
- 664 CARPENTER, G.H. 2013. The secretion, components, and properties of saliva. *Annual Review*  
665 *and Food Science and Technology* 4, 267-276.
- 666 CHAUDHURY, N.M.A, SHIRLAW, P., PRAMANIK, R., CARPENTER, G.H., and  
667 PROCTOR, G.B. 2015. Changes in saliva rheological properties and mucin  
668 glycosylation in dry mouth. *Journal of Dental Research* 94, 1660-1667.
- 669 CHAUDHURY, N.M.A., PROCTOR, G.B., KARLSSON, N.G., CARPENTER, G.H., and  
670 FLOWERS, S.A. 2016. Reduced Mucin-7 (Muc7) sialylation and altered saliva  
671 rheology in Sjögren's syndrome associated oral dryness. *Molecular & Cellular*  
672 *Proteomics* 15, 1048.
- 673 CHEN, J, H.R., HU, X., WANG, X., and YUAN, B. 2019. Artificial saliva containing okra  
674 extract and preparation method and application thereof. Patent number CN109662981A
- 675 CHRISTERSSON, C.E., LINDH, L., and ARNEBRANT, T. 2000. Film-forming properties  
676 and viscosities of saliva substitutes and human whole saliva. *European Journal of Oral*  
677 *Sciences* 108, 418-425.
- 678 COLES, J.M., CHANG, D.P., and ZAUSCHER, S. 2010. Molecular mechanisms of aqueous  
679 boundary lubrication by mucinous glycoproteins. *Current Opinion in Colloid &*  
680 *Interface Science* 15, 406-416.
- 681 DA MATA, A.D., DA SILVA MARQUES, D.N., SILVEIRA, J.M., MARQUES, J.R., DE  
682 MELO CAMPOS FELINO, E.T., and GUILHERME, N.F. 2009. Effects of gustatory  
683 stimulants of salivary secretion on salivary pH and flow: a randomized controlled trial.  
684 *Oral Diseases* 15, 220-228.
- 685 DAVIES, A.N. 2000. A comparison of artificial saliva and chewing gum in the management  
686 of xerostomia in patients with advanced cancer. *Palliative Medicine* 14, 197-203.
- 687 DE VICENTE, J., STOKES, J.R., and SPIKES, H.A. 2005. Lubrication properties of non-  
688 adsorbing polymer solutions in soft elastohydrodynamic (EHD) contacts. *Tribology*  
689 *International* 38, 515-526.
- 690 DIJKEMA, T., TERHAARD, C.H., ROESINK, J.M., RAAIJMAKERS, C.P., VAN DEN  
691 KEIJBUS, P.A., BRAND, H.S., and VEERMAN, E.C. 2012. MUC5B levels in  
692 submandibular gland saliva of patients treated with radiotherapy for head-and-neck  
693 cancer: a pilot study. *Radiation Oncology* (London, England) 7, 91.
- 694 DODDS, M., ROLAND, S., EDGAR, M., and THORNHILL, M. 2015. Saliva A review of its  
695 role in maintaining oral health and preventing dental disease. *British Dental Journal*  
696 *(BDJ) Team* 2, 15123.
- 697 ELIASSON, L., and CARLÉN, A. 2010. An update on minor salivary gland secretions.  
698 *European Journal of Oral Sciences*, 118, 435-442.
- 699 EVESON, J.W. 2008. Xerostomia. *Periodontology*, 48, 85-91.
- 700 FOX, P.C., BUSCH, K.A., and BAUM, B.J. 1987. Subjective reports of xerostomia and  
701 objective measures of salivary gland performance. *Journal of the American Dental*  
702 *Association* (1939) 115, 581-584.
- 703 FURNESS, S., WORTHINGTON, H.V., BRYAN, G., BIRCHENOUGH, S., and  
704 MCMILLAN, R. 2011. Interventions for the management of dry mouth: topical  
705 therapies. *The Cochrane Database of Systematic Reviews*, Cd008934.
- 706 GARBERS, C., MERCK, K.B., KLETER, G.A., VEREIJKEN, J. M., and RAISING, G. F. J.  
707 2003. Oral care products containing ovomucin. Patent number US2005226822A1.
- 708 GIL-MONTOYA, J.A., SILVESTRE, F.J., BARRIOS, R., and SILVESTRE-RANGIL, J. 2016.  
709 Treatment of xerostomia and hyposalivation in the elderly: A systematic review.  
710 *Medicina Oral, Patología Oral y Cirugía Bucal* 21, e355-366.

711 GITTINGS, S., TURNBULL, N., HENRY, B., ROBERTS, C.J., and GERSHKOVICH, P.  
712 2015. Characterisation of human saliva as a platform for oral dissolution medium  
713 development. *European journal of Pharmaceutics and Biopharmaceutics*, 91, 16-24.

714 GRANOT, M., and NAGLER, R.M. 2005. Association between regional idiopathic neuropathy  
715 and salivary involvement as the possible mechanism for oral sensory complaints. *The*  
716 *Journal of Pain*, 6, 581-587.

717 GUGGENHEIMER, J., and MOORE, P.A. 2003. Xerostomia: etiology, recognition and  
718 treatment. *Journal of the American Dental Association* 134, 61-69; quiz 118-119.

719 HAN, P., SUAREZ-DURALL, P., and MULLIGAN, R. 2015a. Dry mouth: A critical topic for  
720 older adult patients. *Journal of Prosthodontic Research* 59, 6-19.

721 HATTON, M.N., LEVINE, M.J., MARGARONE, J.E., and AGUIRRE, A. 1987. Lubrication  
722 and viscosity features of human saliva and commercially available saliva substitutes.  
723 *Journal of Oral and Maxillofacial Surgery*, 45, 496-499.

724 HE, P., DAVIS, S.S., and ILLUM, L. 1998. In vitro evaluation of the mucoadhesive properties  
725 of chitosan microspheres. *International Journal of Pharmaceutics* 166, 75-88.

726 HOPCRAFT, M.S., and TAN, C. 2010. Xerostomia: an update for clinicians. *Australian Dental*  
727 *Journal* 55, 238-244.

728 HU, J., ANDABLO-REYES, E., SOLTANAHMADI, S. and SARKAR, A. 2020. Synergistic  
729 microgel-reinforced hydrogels as high-performance lubricants. *ACS Macro Letters* 9,  
730 1726-1731

731 JELLEMA, A.P., DOORNAERT, P., SLOTMAN, B.J., LEEMANS, C. R., and  
732 LANGENDIJK, J.A. 2005. Does radiation dose to the salivary glands and oral cavity  
733 predict patient-rated xerostomia and sticky saliva in head and neck cancer patients  
734 treated with curative radiotherapy? *Radiotherapy and Oncology*: 77, 164-71.

735 KELLY, H.M., DEASY, P.B., BUSQUET, M., and TORRANCE, A.A. 2004. Bioadhesive,  
736 rheological, lubricant and other aspects of an oral gel formulation intended for the  
737 treatment of xerostomia. *International Journal of Pharmaceutics* 278, 391-406.

738 KHO, H.-S., and PARK, M. 2011. Artificial saliva comprising extracted yam mucilage. Patent  
739 number KR101291413B1.

740 KHO, H.-S. 2014. Understanding of xerostomia and strategies for the development of artificial  
741 saliva. *The Chinese Journal of Dental Research* 17, 75-83.

742 LASHLEY, K.S. 1916. Reflex secretion of the human parotid gland. *Journal of Experimental*  
743 *Psychology* 1, 461-493.

744 LEE, J.W., PARK, J.H., and ROBINSON, J.R. 2000. Bioadhesive-based dosage forms: The  
745 next generation. *Journal of Pharmaceutical Sciences* 89, 850-866.

746 LÖFGREN, C.D., WICKSTRÖM, C., SONESSON, M., LAGUNAS, P.T., and  
747 CHRISTERSSON, C. 2012. A systematic review of methods to diagnose oral dryness  
748 and salivary gland function. *BMC Oral Health* 12, 29.

749 LOMBAERT, I.M., BRUNSTING, J.F., WIERENGA, P.K., FABER, H., STOKMAN, M.A.,  
750 KOK, T., VISSER, W.H., KAMPINGA, H.H., DE HAAN, G., and COPPES, R.P. 2008.  
751 Rescue of salivary gland function after stem cell transplantation in irradiated glands.  
752 *PloS One* 3, e2063.

753 ŁYSIK, D., NIEMIROWICZ-LASKOWSKA, K., BUCKI, R., TOKAJUK, G., and  
754 MYSTKOWSKA, J. 2019. Artificial aaliva: challenges and future perspectives for the  
755 treatment of xerostomia. *International Journal of Molecular Sciences* 20, 3199.

756 MARTIRE, M.V., SANTIAGO, M.L., CAZENAVE, T., and GUTIERREZ, M. 2018. Latest  
757 advances in ultrasound assessment of salivary glands in Sjögren syndrome. *Journal of*  
758 *Clinical Rheumatology* 24, 218-233.

759 MORTAZAVI, H., BAHARVAND, M., MOVAHHEDIAN, A., MOHAMMADI, M., and  
760 KHODADOUSTAN, A. 2014. Xerostomia due to systemic disease: a review of 20

761 conditions and mechanisms. *Annals of Medical and Health Sciences Research* 4, 503-  
762 510.

763 MORZEL, M., SIYING, T., BRIGNOT, H., and LHERMINIER, J. 2014. Immunocytological  
764 detection of salivary mucins (MUC5B) on the mucosal pellicle lining human epithelial  
765 buccal cells. *Microscopy Research and Technique* 77, 453-457.

766 NAKAMOTO, R. and RYOJI, Y. 2004. Oral composition, method for producing the same, and  
767 method for using the same. Patent number JP2005104966A.

768 NARHI, T.O., MEURMAN, J.H., and AINAMO, A. 1999. Xerostomia and hyposalivation:  
769 causes, consequences and treatment in the elderly. *Drugs Aging* 15, 103-116.

770 NAVAZESH, M. 1993. Methods for collecting saliva. *Annals of the New York Academy of*  
771 *Sciences* 694, 72-77.

772 NAVAZESH, M., and CHRISTENSEN, C.M. 1982. A comparison of whole mouth resting and  
773 stimulated salivary measurement procedures. *Journal of Dental Research* 61, 1158-  
774 1162.

775 NAVAZESH, M., and KUMAR, S.K.S. 2008. Measuring salivary flow: Challenges and  
776 opportunities. *The Journal of the American Dental Association* 139, 35S-40S.

777 NIEUW AMERONGEN, A.V., and VEERMAN, E.C. 2003. Current therapies for xerostomia  
778 and salivary gland hypofunction associated with cancer therapies. *Supportive Care in*  
779 *Cancer* 11, 226-231.

780 OH, D.J., LEE, J.Y., KIM, Y.K., and KHO, H.S. 2008. Effects of carboxymethylcellulose  
781 (CMC)-based artificial saliva in patients with xerostomia. *International Journal of Oral*  
782 *and Maxillofacial Surgery* 37, 1027-1031.

783 ORELLANA, M.F., LAGRAVÈRE, M.O., BOYCHUK, D.G., MAJOR, P.W., and FLORES-  
784 MIR, C. 2006. Prevalence of xerostomia in population-based samples: a systematic  
785 review. *Journal of Public Health Dentistry* 66, 152-158.

786 OTA, Y., MORITO, A., FUJISAWA, K., NISHIDA, M., HATA, H., UENO, T., YURIKUSA,  
787 T., and MURATA, T. 2012. Evaluation of a moisturising micro-gel spray for prevention  
788 of cell dryness in oral mucosal cells: an in vitro study and evaluation in a clinical setting.  
789 *European Journal of Cancer Care (Engl)* 21, 728-34.

790 PAI, S., GHEZZI, E.M., and SHIP, J.A. 2001. Development of a Visual Analogue Scale  
791 questionnaire for subjective assessment of salivary dysfunction. *Oral surgery, Oral*  
792 *Medicine, Oral Pathology, Oral Radiology, and Endodontics* 91, 311-316.

793 PAILLER-MATTEI, C., VARGIOLU, R., TUPIN, S., and ZAHOUANI, H. 2015. Ex vivo  
794 approach to studying bio-adhesive and tribological properties of artificial salivas for  
795 oral dryness (xerostomia). *Wear* 332-333, 710-714.

796 PARK, H., and ROBINSON, J.R. 1987. Mechanisms of mucoadhesion of poly(acrylic acid)  
797 hydrogels. *Pharmaceutical Research* 4, 457-464.

798 PARTENHAUSER, A., and BERNKOP-SCHNÜRCH, A. 2016. Mucoadhesive polymers in  
799 the treatment of dry X syndrome. *Drug Discovery Today* 21.

800 PEDERSEN, A.M.L., BARDOW, A., and NAUNTOFTE, B. 2005. Salivary changes and  
801 dental caries as potential oral markers of autoimmune salivary gland dysfunction in  
802 primary Sjögren's syndrome. *BMC Clinical Pathology* 5, 4.

803 PERCIVAL, R.S., CHALLACOMBE, S.J., and MARSH, P.D. 1994. Flow rates of resting  
804 whole and stimulated parotid saliva in relation to age and gender. *Journal of Dental*  
805 *Research* 73, 1416-1420.

806 PUSHPASS, R.-A.G., DALY, B., KELLY, C., PROCTOR, G., and CARPENTER, G.H. 2019a.  
807 Altered salivary flow, protein composition, and rheology following taste and TRP  
808 stimulation in older adults. *Frontiers in Physiology* 10, 652-652.

809 PUSHPASS, R.-A.G., PELLICCIOTTA, N., KELLY, C., PROCTOR, G., and CARPENTER,  
810 G.H. 2019b. Reduced salivary mucin binding and glycosylation in older adults  
811 influences taste in an in vitro cell model. *Nutrients* 11, 2280.

812 QIAN, J. 2013. Formulation for treatment of dry mouth and mouth sores. Patent number  
813 US2014093582A1.

814 RILEY, P., GLENNY, A.M., HUA, F., and WORTHINGTON, H.V. 2017 Pharmacological  
815 interventions for preventing dry mouth and salivary gland dysfunction following  
816 radiotherapy. *Cochrane Database Systematic Review*, 31, 7.

817 PRENCIPE, C., RUSSO, A., STETTLER, H., and MORGAN, A.M. 2016. Oral care  
818 compositions and methods of use. Patent number WO2017003844A1.

819 RODRIGUEZ-VILABOIA, D. 2008. Composition for treating xerostomia or dry mouth. Patent  
820 number US8540970B2.

821 SAHA, D., and BHATTACHARYA, S. 2010. Hydrocolloids as thickening and gelling agents  
822 in food: a critical review. *Journal of Food Science and Technology* 47, 587-597.

823 SALUM, F.G., MEDELLA-JUNIOR, F.A.C., FIGUEIREDO, M.A.Z., and CHERUBINI, K.  
824 2018. Salivary hypofunction: An update on therapeutic strategies. *Gerodontology* 35,  
825 305-316.

826 SAMUNI, Y., and BAUM, B.J. 2011. Gene delivery in salivary glands: From the bench to the  
827 clinic. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* 1812, 1515-  
828 1521.

829 SARKAR, A., ANDABLO-REYES, E., BRYANT, M., DOWSON, D., and NEVILLE, A.  
830 2019a. Lubrication of soft oral surfaces. *Current Opinion in Colloid & Interface*  
831 *Science* 39, 61-75.

832 SARKAR, A., XU, F., and LEE, S. 2019b. Human saliva and model saliva at bulk to adsorbed  
833 phases – similarities and differences. *Advances in Colloid and Interface Science* 273,  
834 102034.

835 SARKAR, A., YE, A., and SINGH, H. 2017. Oral processing of emulsion systems from a  
836 colloidal perspective. *Food & Function* 8, 511-521.

837 SASANO, T., SATOH-KURIWADA, S., and SHOJI, N. 2015, The important role of umami  
838 taste in oral and overall health. *Flavour* 4, 10..

839 SCHEIN, O.D., HOCHBERG, M.C., MUÑOZ, B., TIELSCH, J.M., BANDEEN-ROCHE, K.,  
840 PROVOST, T., ANHALT, G.J., and WEST, S. 1999. Dry eye and dry mouth in the  
841 elderly: A population-based assessment. *Archives of Internal Medicine* 159, 1359-1363.

842 SCOTT, D. C., SALLOUM, D.S., SNIDER, A. G., and JOHNSON, C.L. 2010. Oral  
843 compositions for treatment of dry mouth. Patent number EP2496204A2.

844 SEE, L., MOHAMMADI, M., HAN, P.P., MULLIGAN, R., and ENCISO, R. 2019. Efficacy  
845 of saliva substitutes and stimulants in the treatment of dry mouth. *Special Care in*  
846 *Dentistry* 39, 287-297.

847 SERRA, L., DOMÉNECH, J., and PEPPAS, N.A. 2006. Design of poly(ethylene glycol)-  
848 tethered copolymers as novel mucoadhesive drug delivery systems. *European Journal*  
849 *of Pharmaceutics and Biopharmaceutics* 63, 11-18.

850 SHAHDAD, S.A., TAYLOR, C., BARCLAY, S.C., STEEN, I.N., and PRESHAW, P.M. 2005.  
851 A double-blind, crossover study of Biotène Oralbalance and BioXtra systems as  
852 salivary substitutes in patients with post-radiotherapy xerostomia. *European Journal of*  
853 *Cancer Care* 14, 319-326.

854 SHARMA, P. K., HERRMANN, A., KOLBE, A., and VEEREGOWDA, D. H. 2013.  
855 Biolubricant polypeptides and therapeutic uses thereof. Patent number US9334312B2.

856 SHIP, J.A., PILLEMER, S.R., and BAUM, B.J. 2002. Xerostomia and the geriatric patient.  
857 *Journal of the American Geriatrics Society* 50, 535-543.

858 SINGH, A., CORVELLI, M., UNTERMAN, S.A., WEPASNICK, K.A., MCDONNELL, P.,  
859 and ELISSEEFF, J.H. 2014. Enhanced lubrication on tissue and biomaterial surfaces  
860 through peptide-mediated binding of hyaluronic acid. *Nature Materials* 13, 988-995.

861 SMART, J.D. 2005. The basics and underlying mechanisms of mucoadhesion. *Advanced Drug*  
862 *Delivery Reviews* 57, 1556-1568.

863 SOGIAS, I.A., WILLIAMS, A.C., and KHUTORYANSKIY, V.V. 2008. Why is chitosan  
864 mucoadhesive? *Biomacromolecules* 9, 1837-1842.

865 SPIRK, C., HARTL, S., PRITZ, E., GUGATSCHKA, M., KOLB-LENZ, D., LEITINGER, G.,  
866 and ROBLEGG, E. 2019. Comprehensive investigation of saliva replacement liquids  
867 for the treatment of xerostomia. *International Journal of Pharmaceutics* 571, 118759.

868 SUH, K.I., LEE, J.Y., CHUNG, J.W., KIM, Y.K., and KHO, H.S. 2007. Relationship between  
869 salivary flow rate and clinical symptoms and behaviours in patients with dry mouth.  
870 *Journal of Oral Rehabilitation* 34, 739-744.

871 TANASIEWICZ, M., HILDEBRANDT, T., and OBERSZTYN, I. 2016. Xerostomia of  
872 Various Etiologies: A Review of the Literature. *Advances in Clinical and Experimental*  
873 *Medicine* 25, 199-206.

874 THOMSON, W.M., CHALMERS, J.M., SPENCER, A.J., and WILLIAMS, S.M. 1999. The  
875 Xerostomia Inventory: a multi-item approach to measuring dry mouth. *Community*  
876 *Dental Health* 16, 12-17.

877 THOMSON, W.M., and WILLIAMS, S.M. 2000. Further testing of the xerostomia inventory.  
878 *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics* 89,  
879 46-50.

880 THOMSSON, K.A., PRAKOBPHOL, A., LEFFLER, H., REDDY, M.S., LEVINE, M.J.,  
881 FISHER, S.J., and HANSSON, G.C. 2002. The salivary mucin MG1 (MUC5B) carries  
882 a repertoire of unique oligosaccharides that is large and diverse. *Glycobiology* 12, 1-14.

883 VAINSHTEIN, J.M., SAMUELS, S., TAO, Y., LYDEN, T., HAXER, M., SPECTOR, M.,  
884 SCHIPPER, M., and EISBRUCH, A. 2016. Impact of xerostomia on dysphagia after  
885 chemotherapy-intensity-modulated radiotherapy for oropharyngeal cancer:  
886 Prospective longitudinal study. *Head & Neck* 38, E1605-E1612.

887 VAN DER PUTTEN, G.J., BRAND, H.S., SCHOLS, J.M., and DE BAAT, C. 2011. The  
888 diagnostic suitability of a xerostomia questionnaire and the association between  
889 xerostomia, hyposalivation and medication use in a group of nursing home residents.  
890 *Clinical Oral Investigations* 15, 185-192.

891 VAN DER REIJDEN, W.A., VAN DER KWAAK, H., VISSINK, A., VEERMAN, E.C., and  
892 AMERONGEN, A.V. 1996. Treatment of xerostomia with polymer-based saliva  
893 substitutes in patients with Sjögren's syndrome. *Arthritis and Rheumatism* 39, 57-63.

894 VAN DER REIJDEN, W.A., VEERMAN, E.C., and NIEUW AMERONGEN, A.V. 1994.  
895 Rheological properties of commercially available polysaccharides with potential use in  
896 saliva substitutes. *Biorheology* 31, 631-642.

897 VEEREGOWDA, D.H., BUSSCHER, H.J., VISSINK, A., JAGER, D.-J., SHARMA, P.K.,  
898 and VAN DER MEI, H.C. 2012. Role of structure and glycosylation of adsorbed protein  
899 films in biolubrication. *PloS One* 7, e42600-e42600.

900 VILLA, A., and ABATI, S. 2011. Risk factors and symptoms associated with xerostomia: a  
901 cross-sectional study. *Australian Dental Journal* 56, 290-295.

902 VINKE, J., KAPER, H.J., VISSINK, A., and SHARMA, P.K. 2020. Dry mouth: saliva  
903 substitutes which adsorb and modify existing salivary condition films improve oral  
904 lubrication. *Clinical Oral Investigations*.

905 VISSINK, A., DE JONG, H.P., BUSSCHER, H.J., ARENDS, J., and GRAVENMADE, E.J.  
906 1986. Wetting properties of human saliva and saliva substitutes. *Journal of Dental*  
907 *Research* 65, 1121-1124.



908 VISSINK, A., S-GRAVENMADE, E.J., PANDERS, A.K., VERMEY, A., PETERSEN, J.K.,  
909 VISCH, L.L., and SCHAUB, R.M. 1983. A clinical comparison between commercially  
910 available mucin- and CMC-containing saliva substitutes. *International Journal of Oral*  
911 *Surgery* 12, 232-238.

912 WAN, H., VISSINK, A., and SHARMA, P.K. 2020. Enhancement in xerostomia patient  
913 salivary lubrication using a mucoadhesive. *Journal of Dental Research*,  
914 22034520917675.

915 WICKSTRÖM, C., DAVIES, J.R., ERIKSEN, G.V., VEERMAN, E.C., and CARLSTEDT, I.  
916 1998. MUC5B is a major gel-forming, oligomeric mucin from human salivary gland,  
917 respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage.  
918 *Biochemical Journal* 334 ( Pt 3), 685-693.

919 WLASCHIN, K.F., ENGLER, A.C., COHEN, H.C., WANG, Y., GONG, T., TON, T.,  
920 OXMAN, J. D., YANG, J., and RUSIN, R. P. 2018. Oral plant-based-oil-in-water  
921 emulsions and methods of use. Patent number WO2019102354A1.

922 XU, F., LAGUNA, L., and SARKAR, A. 2019. Aging-related changes in quantity and quality  
923 of saliva: Where do we stand in our understanding? *Journal of Texture Studies*, 27-35.

924 XU, F., LIAMAS, E., BRYANT, M., ADEDEJI, A.F., ANDABLO-REYES, E.,  
925 CASTRONOVO, M., ETTELAIE, R., CHARPENTIER, T.V.J., and SARKAR, A.  
926 2020. A self-assembled binary protein model explains high-performance salivary  
927 lubrication from macro to nanoscale. *Advanced Materials Interfaces* 7, 1901549.

928 YAKUBOV, G.E., MACAKOVA, L., WILSON, S., WINDUST, J.H.C., and STOKES, J.R.  
929 2015. Aqueous lubrication by fractionated salivary proteins: Synergistic interaction of  
930 mucin polymer brush with low molecular weight macromolecules. *Tribology*  
931 *International* 89, 34-45.

932

933

934 **Tables**

935 **Table 1.** A list of abbreviation used in this review article.

<b>Abbreviation</b>	<b>Meaning</b>
BX	BioXtra
COOH	carboxylic moiety
CMC	carboxymethyl cellulose
HEC	hydroxyethyl cellulose
HA	hyaluronic acid
HPC	hydroxypropyl cellulose
MC	methyl cellulose
MTM	mini traction machine
OB	Biotène Oral balance dry mouth system
PTH	parathyroid hormone
PAA	polyacrylic acid
PEG	polyethylene glycol
pSS	primary Sjögren's syndrome
QCM-D	quartz crystal microbalance with dissipation
VAS	visual analogue scale
XI	Xerostomia Inventory

936

937

938

939

940

941

942  
943  
944

**Table 2.** Questionnaires for subjective diagnosis of dry mouth and their relationship with salivary flow rates.

Questions/statements	Rating scales/ Scores	Correlation with salivary flow rate	Reference
<b>Fox et al Questionnaire</b>			
1. Does your mouth feel dry at night or on awakening? 2. Does your mouth feel dry at other times of the day? 3. Do you keep a glass of water by your bed? 4. Do you chew gum daily to relieve oral dryness? 5. Do you use hard candies or mints daily to relieve oral dryness? 6. Do you sip liquids to aid in swallowing dry foods? 7. Does your mouth feel dry when eating a meal? 8. Do you have difficulties swallowing any foods? 9. Does the amount of saliva in your mouth seem to be too little, too much, or you don't notice it?	Binary scale (Positive or negative answer)	Question 1-5 were not indicative of a decreased salivary output (stimulated and unstimulated salivary flow), while the responses to questions 6-9 were highly indicative of diminished salivary output.	(Fox <i>et al.</i> , 1987)
<b>The Xerostomia Inventory</b>			
1. I sip liquids to help swallow food 2. My mouth feels dry when eating a meal 3. I get up at night to drink 4. My mouth feels dry 5. I have difficulty in eating dry food 6. I suck sweets or cough lollies to relieve dry mouth 7. I have difficulties swallowing certain foods 8. The skin of my face feels dry 9. My eyes feel dry 10. My lips feel dry 11. The inside of my nose feels dry	Categorical scoring scale Never, hardly, occasionally, fairly often and very often (scoring 1-5, respectively)	The single Xerostomia Inventory (XI) scale score has a very low correlation with resting salivary flow rate but a much stronger correlation with the standard dry mouth question responses.	(Thomson <i>et al.</i> , 1999)
<b>Visual Analogue Scale questionnaire for subjective assessment of salivary dysfunction</b>			
1. Rate the difficulty you experience in speaking due to dryness 2. Rate the difficulty you experience in swallowing due to dryness 3. Rate how much saliva is in your mouth 4. Rate the dryness of your mouth 5. Rate the dryness of your throat 6. Rate the dryness of your lips 7. Rate the dryness of your tongue 8. Rate the level of your thirst	Visual Analog Scale (100-mm horizontal scale)	Significant reliability for 7 VAS items (excluding item 3). Five items (1, 2, 3, 5 and 6) show significant validity with unstimulated submandibular saliva flow rates. Two items (1 and 6) show significant validity with stimulated submandibular flow rates. Only item 2 was significantly correlated for	(Pai <i>et al.</i> , 2001)

stimulated parotid flow rates.

---

*Combination questionnaire*

---

1. Duration of oral dryness	Combination of binary scale, categorical and VAS:	Dry mouth-related symptoms and behaviours (question 3a-3f) are significantly associated with whole salivary flow rate. While question 1, 2 and 7 are not significantly associated with salivary flow rate.	(Suh <i>et al.</i> , 2007)
2. Frequency of oral dryness			
3a. Oral dryness at night or on awakening	1. Recently, Several months, Several years		
3b. Oral dryness at other times of the day	2. Occasionally, Frequently, Always		
3c. Oral dryness during eating	3. Visual Analog Scale (0-10, 10 means worst possible)		
3d. Difficulty in swallowing foods			
3e. Amount of saliva in usual, everyday life			
3f. Effect of oral dryness on daily life			
4. Awakening from sleep at night because of oral dryness	4 and 5. Never, 1-2 per week, 3-4 per week, 5-6 per week, Everyday		
5. Taking a water to bed			
6. Sipping liquids to aid in swallowing dry foods			
7. Using candy or chewing gum because of oral dryness	6 and 7. Never, Occasionally, Frequently, Always		
8. Dry mouth-associated complaints (sensation of burning mouth, taste disturbances and oral malodour)	8. Yes/No		

---

945

946


947  
948

**Table 3.** Patents on inventions of salivary substitute formulations for dry mouth therapy filed in the last 20 years (Source of database: Espacenet).

Patent number	Filing date	Assignee	Key technology in the invention	Property evaluation of the formulation (invention)	Reference
JP2005104966A	2004-06-30	Lion Corp	Microgel particle	(A) Average particle size measurement (B) Viscosity measurement (C) Evaluation of appearance, usage, dispersion stability and spray ability (D) Clinical test (n= 20 healthy persons) for the evaluation of residual feeling in the oral cavity and cleaning feeling between teeth and gums	(Nakamoto and Ryoji, 2004)
US2005226822A1	2003-04-25	Gaba International Ag	Mannoprotein and ovomucin	(A) Rheological behaviour measurement	(Garbers <i>et al.</i> , 2003)
US8540970B2	2008-02-22	Biocosmetic SL	Olive oil, trimethylglycine and xylitol	(A) Clinical test (n=20 xerostomia patients) of unstimulate salivary flow rate at the beginning and after one week of application of composition (B) Clinical test by xerostomia VAS questionnaire	(Rodriguez-Vilaboa, 2008)
KR101291413B1	2011-08-22	Seoul National University Industry-Academic Cooperation Foundation	Yam mucilage extraction	(A) Viscosity measurement (B) Lysozyme or peroxidase activity in solution	(Kho and Park 2011)
WO2012095774A1	2012-01-06	Indian Institute of Technology, Bombay, India	Gellan gum linked with dipalmitoylphosphatidylcholine and palmitoyloleoyl phosphatidylethanolamine	(A) Fourier-transform infrared spectroscopy of composition (B) Surface pressure (C) Amphiphilic nature (D) Viscosity measurement (E) Viscoelasticity measurement (F) Atomic force microscopy of the formed films (G) Height and roughness analysis (H) Particle size analysis	(Banerjee and GuhaSarkar, 2012)
US2014093582A1	2013-09-24	Golden Pearl Investment LLC	Serum composition	(A) Evaluation of the effect of serum extract on cell growth. (B) Clinical test (n= 32 healthy female volunteers)	(Qian, 2013)

US9334312B2	2013-10-04	Rijksuniversiteit Groningen, Academisch Ziekenhuis Groningen	Recombinant cationic polypeptides	to evaluate the effect of formulation (invention) on skin, focusing on satisfactory of maintenance, absorbance, moisturizing and so on. (C) Animal test (n= 4 mice) to evaluate the effect of the formulation (invention) on burn injury. (A) Adsorption test on salivary conditioning films. (B) Friction forces, repulsive force and glycosylation testa.	(Sharma <i>et al.</i> , 2013)
WO2018212771A1	2016-06-24	Colgate-Palmolive Company	Combination of hemp seed oil and caprylyl glycol	(A) Friction measurement. (B) <i>In vitro</i> test of moisture retention.	(Prencipe <i>et al.</i> , 2016)
WO2019102354A1	2018-11-20	3M Innovative Properties Company	Emulsion (oil in water): combination of plant based oils, an aqueous phase, surfactants and viscosity modifier.	(A) Viscosity measurement. (B) Friction measurement. (C) Stability (no phase separation) measurement. (D) High temperature stability test. (E) Freeze/ Thaw/ Centrifugation stability measurement. (F) Spray-ability measurement. (G) <i>In vitro</i> hydration retention measurement (Thermal gravimetric Analysis). (H) Long term wash-off measurement (with artificial saliva) (I) Biofilm disruption test (J) Bovine tooth hardness measurement	(Wlaschin <i>et al.</i> , 2018)
CN109662981A	2019-01-28	UNIV Zhejiang Gongshang	Okra extraction	(A) Shear rheological property test (B) Friction coefficient test (C) Oral tensile rheological properties test (D) Taste test (n=30 healthy participants)	(Chen <i>et al.</i> , 2019)

950




951

952

953 **Figure 1.** Diagnosis of dry mouth conditions by visual imaging of (A) an extreme dry  
954 mouth condition due to primary Sjögren's syndrome (pSS) and ultrasound images of the  
955 parotid gland in a healthy people (B1) and in a pSS patient (B2) where multi-hypoechoic  
956 areas reflect salivary gland damage. Images have been captured by co-author Dr. Alan  
957 Mighell in Leeds Teaching Hospitals NHS Trust, UK.

958



959

960

961 **Figure 2.** Potential dry mouth diagnostic tests of saliva. (a) relative levels of sulfo-MUC5B


962 in labial salivary glands from Sjögren syndrome patients and control group (Alliende *et al.*,

963 2008) (Reproduced with permission from BMJ Publishing Group Ltd. & European League



964 Against Rheumatism), (b) Spinnbarkeit measurement of saliva in the groups of patients  
965 with dry mouth patients and healthy controls (Chaudhury *et al.*, 2015) (Reproduced with  
966 permission from SAGE Publications), (c) viscosity of unstimulated saliva (US) in different  
967 age (age 20-27 versus 28-35) and gender (female versus male) group as a function of shear  
968 rates (Gittings *et al.*, 2015) (Reproduced with permission from Elsevier), (d) adsorption  
969 profile of whole mouth saliva and parotid saliva measured at 3<sup>rd</sup> overtone by quartz crystal  
970 microbalance with dissipation monitoring (QCM-D) on hydroxyapatite-coated sensors  
971 (Ash *et al.*, 2014) (Reproduced with permission from Elsevier), and (e) friction coefficient  
972 of healthy saliva and Sjögren syndrome patients' saliva at different sliding cycles in an *ex-*  
973 *vivo* tongue-enamel tribological system (Wan *et al.*, 2020) (Reproduced with permission  
974 from SAGE Publications).

975



976

977

978 **Figure 3.** Common ingredients used in commercial salivary substitutes and the rationale

979 behind their use.

980

981